Eli Lilly (LLY) EPS (Weighted Average and Diluted) (QoQ) (2012 - 2026)

Eli Lilly (LLY) EPS (Weighted Average and Diluted) (QoQ) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 11.77%
Dec 31, 2025 19.00%
Sep 30, 2025 -1.27%
Jun 30, 2025 105.56%
Mar 31, 2025 -37.30%
Dec 31, 2024 356.07%
Sep 30, 2024 -67.38%
Jun 30, 2024 32.26%
Mar 31, 2024 2.48%
Dec 31, 2023 4,133.33%
Sep 30, 2023 -103.08%
Jun 30, 2023 30.87%
Mar 31, 2023 -30.37%
Dec 31, 2022 32.92%
Sep 30, 2022 53.33%
Jun 30, 2022 -50.00%
Mar 31, 2022 11.11%
Dec 31, 2021 54.92%
Sep 30, 2021 -20.26%
Jun 30, 2021 2.68%